Cartesian Therapeutics, Inc. RNAC
7.41
(0.21)
(2.76%)
as of 25 Sep
- Market cap
- $230.6M
- P/E
- 0.0×
Follow RNAC
Insider Buys
alert about insiders buying in the last 12 month
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
— | 0.00 | 0.00 | 2.15 |
+8 more quarters Free account |
P/S ratio |
— | 93.05 | 66.95 | 243.58 | |
P/FCF ratio |
— | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
— | (7.46) | (10.57) | (17.04) | |
P/B ratio |
— | 0.00 | 0.00 | 0.00 | |
Price to Tangible BV |
— | 0.00 | 0.00 | 0.00 | |
EV/Sales |
— | 39.74 | 30.80 | 134.18 | |
EV/EBITDA |
— | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
— | (0.97) | (1.17) | (2.32) | |
EV/FCF |
— | (0.91) | (1.09) | (2.14) | |
Quick Ratio |
7.19 | 7.46 | 8.45 | 10.44 | |
Current Ratio |
7.48 | 7.65 | 8.65 | 10.67 | |
Net Debt/EBITDA |
3.34 | 4.58 | 1.60 | 7.01 | |
Debt/Assets |
16.59% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
(0.42) | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.01 | 0.01 | 0.00 | |
Operating CF/Net income |
(1.54) | 0.56 | 0.20 | 0.43 | |
Capex/Depreciation |
(0.35) | (0.04) | (0.81) | (2.13) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 24,952.56% | 1,551.11% | 3,053.54% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 9,120.51% | 865.58% | 1,707.08% | |
Intangible Assets out of Total Assets |
0.15 | 0.17 | 0.16 | 0.13 | |
Share Based Compensation of Revenue |
0.00% | 3,106.41% | 226.40% | 573.01% | |
Graham Net Nets |
— | (1.90) | (1.57) | (0.98) | |
Graham Number |
— | 27.04 | 23.64 | 0.00 | |
Earnings Yield |
— | (95.77%) | (70.87%) | 46.61% | |
Free Cash Flow Yield |
— | (46.85%) | (42.40%) | (25.79%) | |
Revenue per Share |
0.00 | 0.00 | 0.04 | 0.02 | |
Operating CF per Share |
(0.72) | (0.82) | (0.68) | (0.60) | |
Capex per Share |
(0.01) | 0.00 | (0.02) | (0.05) | |
Free Cash Flow per Share |
(0.72) | (0.83) | (0.70) | (0.65) | |
Cash per Share |
5.01 | 4.42 | 4.82 | 5.51 | |
Shareholders Equity per Share |
(4.25) | (5.52) | (4.86) | (1.38) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(4.25) | (5.52) | (4.86) | (1.38) | |
Free Cash Flow |
(21.35) | (22.16) | (18.20) | (16.89) | |
Working Capital |
133.07 | 106.09 | 114.34 | 133.46 | |
Capital Expenditures |
(0.27) | (0.03) | (0.49) | (1.29) | |
Net Current Asset Value |
(290.24) | (314.47) | (293.37) | (261.26) | |
EV/EBIT |
— | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.35 | 0.52 | 2.86 | |
Net Profit Margin |
0.00% | (50,233.33%) | (9,498.20%) | (7,942.92%) | |
Price to Operating Income |
— | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
0.28 | 1.01 | 0.99 | 3.27 | |
Average Payables |
0.75 | 1.85 | 0.79 | 1.37 | |
Average Assets |
353.76 | 348.76 | 365.72 | 414.00 | |
Average Common Equity |
(63.88) | (84.95) | (66.52) | (17.55) |
Columns are period end dates